Esperite
  • Esperite Introduction
  • Contact
  • Esperite Group
    • Board of Directors
    • Esperite
    • Companies
    • Esperite
  • News & Press Releases
  • Presentations & Policies
  • Financial Information
    • Financial Calendar
    • Financial Reports
  • Shareholder Information
    • Shareholder Meetings
    • Advisors
    • Share Graph
    • Historical Price
  • Corporate Governance
  • Cryosave News

Tag: Genoma

ESPERITE (ESP) Q1 consolidated revenue higher compared to budget

May 31, 2017 Financial Reports
Tags
CryoSave, EBITDA, Esperite, Genoma, Market Update, Q1

ESPERITE (ESP) Q1 consolidated revenue higher compared to budget
EBITDA improved compared to budget as a result of cost control

Zutphen, the Netherlands – 31 May 2017

read more

ESPERITE (ESP) has concluded new agreements with its note holders

May 31, 2017 Group News
Tags
Esperite, Genoma, Shareholders

ESPERITE (ESP) has concluded new agreements with its note holders

Zutphen, the Netherlands – 31 May 2017

read more

Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court

May 19, 2017 Group News
Tags
Esperite, Genoma

Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.

Zutphen, The Netherlands, 19 May 2017

read more

Esperite (ESP) – Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)

May 16, 2017 Group News
Tags
Esperite, Genoma

Esperite (ESP) – Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)

Zutphen, The Netherlands, 15 May 2017

read more

ESPERITE N.V.: Stem Cells, Genetic Tests and Pharmaceuticals

November 8, 2016 Group News
Tags
Cell Factory, Crohn’s disease, CryoSave, Esperite, Extracellular vesicles, Genoma, Patent, Type 1 diabetes

Patent granted to Cell Factory in Europe confirms great potential with its exclusive extracellular vesicles in broad therapeutic applications like Crohn’s disease and Type 1 Diabetes.

Zutphen, The Netherlands – 8 November 2016

read more

ESPERITE (ESP) financial results for 2015 published

April 28, 2016 Financial Reports
Tags
CryoSave, Esperite, Financial Results, Genoma

Genoma on a sharp growth for its strategic expansion
CryoSave fell short due to major changes in workflow
Esperite now with stronger markets positions, but late on schedule.

Zutphen, the Netherlands – 28 April 2016

read more

Esperite N.V.: Genoma enters the south african market with Intercare

February 9, 2016 Group News
Tags
Frederic Amar, Genoma, Partnership, South Africa

Genoma continues its intercontinental expansion through a partnership with Intercare, a South African healthcare leader.

Geneva, Switzerland – 9th February 2016

read more

ESPERITE N.V. Trading Update. CryoSave stable, Genoma 45% growth

November 3, 2015 Group News
Financial and business update
Tags
CryoSave, Esperite, Genoma, Q3

ESPERITE N.V. (Euronext: ESP, ‘ESPERITE’, or ‘the Group’) announces its trading update for the quarter ended 30 September 2015.

Zutphen, The Netherlands – 3 November 2015

read more

ESPERITE Trading Update. Q1 confirms strategy and forecasted growth with Genoma

May 19, 2015 Group News
Tags
Esperite, Frederic Amar, Genoma, Q1

ESPERITE N.V. Trading Update. Q1 confirms strategy and forecasted growth with Genoma

The company is now building the future. CryoSave is on track and Genoma shows its ability to support the current published forecasts and ambitious next developments.

Zutphen, The Netherlands – 19 May 2015

read more

ESPERITE upgrades TRANQUILITY, the most complete CE-IVD marked fetal DNA NIPT that accurately detects Down syndrome and other chromosomal abnormalities

April 30, 2015 Group News
Tags
CE-IVD, Down Syndrome, Esperite, Frederic Amar, Genoma, Tranquility

TRANQUILITY, the only CE-IVD certified genetic test for trisomies 21, 18 and 13 that provides, sexual aneuploidies, microdeletions and fetal sex detection, now ready for mass market

Geneva, Switzerland – 30 April 2015

read more

Page 1 of 212»
Events
Recent Publications
esperite_annual_report_2017_lateral_teaser
Categories
  • Financial Reports (70)
  • Financial Reports FR (2)
  • Group News (430)
  • Group News FR (7)
  • Press Clippings (22)
  • Press Release (ENG) (5)
  • Uncategorised (1)
Archives
Calendar
February 2021
M T W T F S S
« Oct    
1234567
891011121314
15161718192021
22232425262728
Recent News
  • ESPERITE N.V. announces the voting results for the Extra-ordinary General Meeting of Shareholders of ESPERITE N.V. held on Wednesday 30 September 2020. October 5, 2020
  • ESPERITE N.V. announces that due to sanitary constraints the Extraordinary General Meeting of Shareholders scheduled on 30 September 2020 will be organized by audio and video conference. September 18, 2020
  • ESPERITE N.V. convenes Extraordinary General Meeting of Shareholders to approve external financing August 19, 2020
  • Esperite NV announces a major change in its management and appoints its new CEO, Mr. Hugo Brugière. August 5, 2020
  • Esperite secures external financing of up to EUR 35 million of convertible notes with warrants drawable under certain conditions July 28, 2020
Tags
Acquisition AGM Agreement Annual Report Annual Report 2018 Appointment Board Change Cell Factory CEO Cerebral Palsy CF-MEV-117 Cryo-Save CryoSave EGM Esperite European Select Growth Opportunities Fund EVs Extracellular vesicles Financial Reports Financial Results France Frederic Amar Genoma India Investment L1 Capital Media New Funding NYSE Euronext Amsterdam Patent PBKM Q1 Q3 Serbia Shareholders Shareholding Shares South Africa Spain Stem Cells Storage Strategy Switzerland Umbilical Cord Blood Warrants
Contact Information

Esperite N.V.

Email: ir@esperitegroup.com

Important Links
News
Subscribe
Please click here to subscribe for our press releases.
Copyright Esperite NV November 2020
  • Esperite Introduction
  • Media Center
  • Terms of Use
  • Contact